Plasma Proteomic Signatures for Alzheimer's Disease and Related Dementias

阿尔茨海默病和相关痴呆症的血浆蛋白质组学特征

• 批准号: 10524420
• 负责人: Linda Kathleen McEvoy
• 金额: $ 752.32万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10524420
• 关键词: Age; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid beta-42; Biological; Biological Markers; Biological Process; Black race; Blood; Blood Tests; Blood specimen; Chronology; Cognitive; Cohort Studies; Communities; Data; Dementia; Development; Diagnosis; Disease; Enzyme-Linked Immunosorbent Assay; Functional disorder; Glial Fibrillary Acidic Protein; Goals; Hispanic; Human; Impaired cognition; Individual; Intervention; Investments; Knowledge; Light; Longevity; Machine Learning; Measures; Memory; Molecular; Molecular Profiling; Neuronal Injury; Outcome; Pathogenesis; Pathology; Pathway interactions; Persons; Phase; Phenotype; Plasma; Proteins; Proteome; Proteomics; Resources; Risk; Sampling; Sex Differences; Subgroup; Woman; Women' s Health; age related; aging brain; biomarker signature; cerebral atrophy; clinically relevant; cognitive function; cohort; data preservation; data resource; dementia risk; endophenotype; follow-up; high risk; improved; insight; men; mild cognitive impairment; molecular subtypes; neurofilament; neuroimaging; new therapeutic target; novel; patient stratification; personalized intervention; phenotypic data; pre-clinical; precision medicine; predictive marker; predictive signature; proteomic signature; racial diversity; risk stratification; therapeutic target

There is a great need to determine molecular signatures of Alzheimer’s disease (AD) to better understand AD pathophysiology, to detect AD in the preclinical stage, and to identify novel therapeutic targets. The plasma proteome is an ideal resource in which to identify molecular signatures, as proteins perform essential biological functions, are direct therapeutic targets, and shed light on disease mechanisms. Our preliminary data identified several plasma proteomic biomarkers associated with cognitive impairment and AD-related brain atrophy. We also found that accelerated biological (i.e., proteomic) aging relative to chronological age, as measured by our validated proteomic signature of aging (known as a ‘proteomic clock’), was associated with higher risk of multiple age-related conditions, including cognitive impairment. Yet, study of the proteomic changes preceding AD is still in its early stages. The objective of this study is to improve understanding of the proteomics of AD and related dementias (ADRD) by leveraging a nested case-cohort of 2,836 women in the racially diverse Women’s Health Initiative Memory Study (WHIMS). WHIMS contains longitudinal cognitive and neuroimaging measures; 1,336 incident cases of MCI and ADRD rigorously ascertained during 26 years of follow-up; rich phenotypic data; and preserved biospecimens. SOMAscan, the most comprehensive proteomics platform measuring 7,000 clinically relevant human proteins across numerous biological pathways, will be used to characterize the proteome longitudinally from blood samples collected at baseline and 14-18 years later. We will also obtain longitudinal plasma biomarkers of AD pathology from these samples. Our central hypotheses are that: (i) accelerated proteomic aging will be associated with higher risk of MCI/ADRD and lower likelihood of cognitively healthy longevity; and (ii) the 7,000-protein SOMAscan will enable identification of novel proteomic biomarkers, signatures, and biological pathways for MCI/ADRD and related endophenotypes. Our Aims are: Aim 1) Determine associations of validated proteomic clocks of aging with incident MCI/ADRD and cognitively healthy longevity (i.e., survival to age 90 without cognitive impairment); Aim 2) Determine associations of the plasma proteome at baseline, and 14-18-year changes in the proteome, with incident MCI/ADRD and cognitively healthy longevity; Aim 3) Relate proteomic clocks of aging and ADRD-associated proteins identified in Aim 2 to neuroimaging measures and plasma biomarkers of AD pathology; and Aim 4) Identify novel multi-protein signatures that predict MCI/ADRD, cognitively healthy longevity, and plasma biomarkers of AD pathology. Key proteins will be validated on a separate platform (ELISA) and replicated in external cohorts. This study will advance understanding of the heterogeneous mechanisms of ADRD pathogenesis and cognitive impairment in aging, identify risk and protective proteomic factors, and suggest candidate proteins for pathophysiology-targeted interventions in ADRD. The novel proteomic data will be a rich and valuable resource for the broader scientific community to identify novel proteomic biomarkers for a wealth of phenotypes, thus having an enduring impact.

为了更好地理解阿尔茨海默病的病理生理学，在临床前阶段检测AD，以及鉴定新的治疗靶点，非常需要确定阿尔茨海默病（AD）的分子特征。血浆蛋白质组是鉴定分子特征的理想资源，因为蛋白质执行基本的生物学功能，是直接的治疗靶点，并揭示疾病机制。我们的初步数据确定了与认知障碍和AD相关脑萎缩相关的几种血浆蛋白质组学生物标志物。我们还发现，加速生物（即，蛋白质组学）衰老相对于实足年龄，如我们验证的衰老蛋白质组学特征（称为“蛋白质组学时钟”）所测量的，与多种年龄相关疾病的更高风险相关，包括认知障碍。然而，对AD前蛋白质组变化的研究仍处于早期阶段。本研究的目的是通过利用种族多样性妇女健康倡议记忆研究（WHIMS）中2，836名妇女的嵌套病例队列，提高对AD和相关痴呆（ADRD）蛋白质组学的理解。WHIMS包含纵向认知和神经影像学测量;在26年的随访中严格确定了1，336例MCI和ADRD事件;丰富的表型数据;和保存的生物标本。SOMAscan是最全面的蛋白质组学平台，可测量多种生物学途径中的7，000种临床相关人类蛋白质，将用于纵向表征基线和14-18年后收集的血液样本中的蛋白质组。我们还将从这些样本中获得AD病理学的纵向血浆生物标志物。我们的中心假设是：（i）加速的蛋白质组老化将与MCI/ADRD的风险较高和认知健康长寿的可能性较低相关;（ii）7，000蛋白质SOMA扫描将能够识别MCI/ADRD和相关内表型的新型蛋白质组生物标志物，签名和生物学途径。我们的目的是：目的1）确定经验证的衰老蛋白质组时钟与MCI/ADRD事件和认知健康长寿的关联（即，目标2）确定基线血浆蛋白质组和蛋白质组14-18年变化与MCI/ADRD事件和认知健康寿命的相关性;目标3）将目标2中鉴定的衰老和ADRD相关蛋白质的蛋白质组时钟与AD病理学的神经成像测量和血浆生物标志物相关联;和目的4）鉴定预测MCI/ADRD、认知健康寿命和AD病理学的血浆生物标志物的新的多蛋白质特征。关键蛋白质将在单独的平台（ELISA）上进行验证，并在外部队列中进行复制。这项研究将促进对ADRD发病机制和衰老中认知障碍的异质性机制的理解，确定风险和保护性蛋白质组学因素，并提出ADRD病理生理靶向干预的候选蛋白质。新的蛋白质组数据将是更广泛的科学界的丰富和宝贵的资源，以确定新的蛋白质组生物标志物的丰富的表型，从而具有持久的影响。